101 related articles for article (PubMed ID: 19825987)
1. Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer.
Lin CI; Whang EE; Donner DB; Jiang X; Price BD; Carothers AM; Delaine T; Leffler H; Nilsson UJ; Nose V; Moore FD; Ruan DT
Mol Cancer Res; 2009 Oct; 7(10):1655-62. PubMed ID: 19825987
[TBL] [Abstract][Full Text] [Related]
2. Autophagy: a new target for advanced papillary thyroid cancer therapy.
Lin CI; Whang EE; Abramson MA; Jiang X; Price BD; Donner DB; Moore FD; Ruan DT
Surgery; 2009 Dec; 146(6):1208-14. PubMed ID: 19958950
[TBL] [Abstract][Full Text] [Related]
3. Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer.
Lin CI; Whang EE; Donner DB; Du J; Lorch J; He F; Jiang X; Price BD; Moore FD; Ruan DT
Mol Cancer Res; 2010 Sep; 8(9):1217-26. PubMed ID: 20736296
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells.
Lin CI; Whang EE; Abramson MA; Donner DB; Bertagnolli MM; Moore FD; Ruan DT
Biochem Biophys Res Commun; 2009 Feb; 379(2):626-31. PubMed ID: 19124005
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated siRNA targeting NOB1 inhibits tumor growth and enhances radiosensitivity of human papillary thyroid carcinoma in vitro and in vivo.
Meng W; Wang PS; Liu J; Xue S; Wang GM; Meng XY; Chen G
Oncol Rep; 2014 Dec; 32(6):2411-20. PubMed ID: 25231838
[TBL] [Abstract][Full Text] [Related]
6. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma.
Chattopadhyay C; El-Naggar AK; Williams MD; Clayman GL
Head Neck; 2008 Aug; 30(8):991-1000. PubMed ID: 18327775
[TBL] [Abstract][Full Text] [Related]
7. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis.
Muñoz-Gámez JA; Martín-Oliva D; Aguilar-Quesada R; Cañuelo A; Nuñez MI; Valenzuela MT; Ruiz de Almodóvar JM; De Murcia G; Oliver FJ
Biochem J; 2005 Feb; 386(Pt 1):119-25. PubMed ID: 15456408
[TBL] [Abstract][Full Text] [Related]
9. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
Wang W; Zhou J; Zhao L; Chen S
Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
[TBL] [Abstract][Full Text] [Related]
10. Silencing NOB1 enhances doxorubicin antitumor activity of the papillary thyroid carcinoma in vitro and in vivo.
Liu J; Dong BF; Wang PS; Ren PY; Xue S; Zhang XΝ; Han Z; Chen G
Oncol Rep; 2015 Mar; 33(3):1551-9. PubMed ID: 25592304
[TBL] [Abstract][Full Text] [Related]
11. Modified Citrus Pectin as a Potential Sensitizer for Radiotherapy in Prostate Cancer.
Conti S; Vexler A; Hagoel L; Kalich-Philosoph L; Corn BW; Honig N; Shtraus N; Meir Y; Ron I; Eliaz I; Lev-Ari S
Integr Cancer Ther; 2018 Dec; 17(4):1225-1234. PubMed ID: 30043669
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers.
Uddin S; Siraj AK; Al-Rasheed M; Ahmed M; Bu R; Myers JN; Al-Nuaim A; Al-Sobhi S; Al-Dayel F; Bavi P; Hussain AR; Al-Kuraya KS
J Clin Endocrinol Metab; 2008 Oct; 93(10):4088-97. PubMed ID: 18682509
[TBL] [Abstract][Full Text] [Related]
14. Nimesulide, a selective COX-2 inhibitor, acts synergistically with ionizing radiation against A549 human lung cancer cells through the activation of caspase-8 and caspase-3.
Kim BM; Won J; Maeng KA; Han YS; Yun YS; Hong SH
Int J Oncol; 2009 May; 34(5):1467-73. PubMed ID: 19360361
[TBL] [Abstract][Full Text] [Related]
15. Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells.
Yeung SC; Xu G; Pan J; Christgen M; Bamiagis A
Cancer Res; 2000 Feb; 60(3):650-6. PubMed ID: 10676649
[TBL] [Abstract][Full Text] [Related]
16. Clodronate-induced cell apoptosis in human thyroid carcinoma is mediated via the P2 receptor signaling pathway.
Yang DM; Teng HC; Chen KH; Tsai ML; Lee TK; Chou YC; Chi CW; Chiou SH; Lee CH
J Pharmacol Exp Ther; 2009 Aug; 330(2):613-23. PubMed ID: 19448140
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
Keane MM; Ettenberg SA; Nau MM; Russell EK; Lipkowitz S
Cancer Res; 1999 Feb; 59(3):734-41. PubMed ID: 9973225
[TBL] [Abstract][Full Text] [Related]
18. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
19. Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin.
Kim TH; Yoo YH; Kang DY; Suh H; Park MK; Park KJ; Kim SH
Int J Oncol; 2009 May; 34(5):1353-62. PubMed ID: 19360347
[TBL] [Abstract][Full Text] [Related]
20. Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas.
Lavra L; Ulivieri A; Rinaldo C; Dominici R; Volante M; Luciani E; Bartolazzi A; Frasca F; Soddu S; Sciacchitano S
J Pathol; 2009 May; 218(1):66-75. PubMed ID: 19199318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
